戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              Floxuridine (5-fluorodeoxyuridine, FdUrd), a U.S. Food a
2 nts 5-fluorouracil and 5-fluorodeoxyuridine (floxuridine), a 5-fluorouracil metabolite.
3 um-labile prodrug of the nucleoside analogue floxuridine, a potent antineoplastic drug used in the cl
4 is through other mechanisms (hydroxyurea and floxuridine) also act synergistically with AZT.
5 ates with the phosphorylated 5-FU nucleoside Floxuridine and demonstrated their enhanced activity aga
6 six cycles of hepatic arterial infusion with floxuridine and dexamethasone plus intravenous fluoroura
7 re enrolled onto a phase I protocol with HAI floxuridine and dexamethasone plus systemic chemotherapy
8  combination of hepatic arterial infusion of floxuridine and intravenous fluorouracil improves the ou
9 ition of chemotherapy, such as capecitabine, floxuridine, and vinblastine, may increase the effective
10  its metabolite 5-fluorodeoxyuridine (FdUrd, floxuridine) are chemotherapy agents that are converted
11                            Patients received floxuridine at doses previously demonstrated as safe in
12  patients) or postoperative hepatic arterial floxuridine combined with intravenous continuous-infusio
13  dengue virus replication in the presence of floxuridine, consistent with thymidine-less stress trigg
14   CONCLUSION The combination of regional HAI floxuridine/dexamethasone and systemic oxaliplatin and i
15 ) or combined with regional hepatic arterial floxuridine (FUDR) (n = 28).
16 followed by hepatic artery infusion (HAI) of floxuridine (FUDR) alternating with systemic fluorouraci
17 every 2 weeks concurrent with 2 weeks of HAI floxuridine (FUDR) and dexamethasone (Dex) every 28 days
18 biliary toxicity may permit salvage HAI with floxuridine (FUDR) in patients whose liver tumors fail t
19 MTD) of systemic irinotecan (CPT-11) and HAI floxuridine (FUDR) plus dexamethasone (DEX) as combinati
20 efit of adjuvant hepatic arterial infusional floxuridine (HAI-FUDR) in addition to modern systemic ch
21 acil (5-FU) and 5-fluorodeoxyuridine (FdUrd, floxuridine) have activity in multiple tumors, and both
22 delivered concurrently with hepatic arterial floxuridine in 128 patients.
23 ylation facilitates UNG2-dependent repair of floxuridine-induced DNA lesions and promotes tumor cell
24 molecules, we observed that methotrexate and floxuridine inhibited dengue virus infections at low mic
25  control with orally treated Gemcitabine- or Floxuridine-nanogel conjugates.
26 g patients with hepatic arterial infusion of floxuridine plus systemic fluorouracil after liver resec
27  focal liver irradiation with hepatic artery floxuridine prolongs survival in patients with unresecta
28 otrexate and by thymidine in the presence of floxuridine, suggesting an unexpected role for thymidine
29 n cancer cell line that is hypersensitive to floxuridine, we show that GSK-3 phosphorylation facilita
30 re highly sensitive to both methotrexate and floxuridine, whereas other RNA viruses (Sindbis virus an
31 On univariate analysis, receipt of HAI-FUDR (floxuridine) within 1 year of IHP was the only factor as
32 e radiation with concurrent hepatic arterial floxuridine would improve survival in patients with unre

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。